Blood Pressure in Down's Syndrome

Richards, B. W.; Enver, Fatima

doi:10.1111/j.1365-2788.1979.tb00049.x

Cited by 29 publications

(26 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding of this study tend to support the findings of these latter researchers. Further, Richards and Enver (1979) found that blood pressure readings increased with age less dramatically in people with Down syndrome than in the nonlearning disabled population. Results of this study again confirm these findings, blood pressure was found to be agerelated in adults with Down syndrome but the rise with age was less marked than seen for the non-learning disabled population.…”

Section: Twomentioning

confidence: 99%

“…Goldhaber et al (1987) had reported values of 121 mmHg systolic and 72 mmHg diastolic for people with Down syndrome. Richards and Enver (1979) found blood pressure readings of 265 Down syndrome people to be significantly below that for age-matched non-learning disabled individuals. The finding of this study tend to support the findings of these latter researchers.…”

Section: Twomentioning

confidence: 99%

See 1 more Smart Citation

Screening of medical problems in adults with Down syndrome

Prasher¹

1994

Downs Syndr. Res. Pract.

View full text Add to dashboard Cite

Section: Twomentioning

confidence: 99%

Section: Twomentioning

confidence: 99%

Screening of medical problems in adults with Down syndrome

Prasher¹

1994

Downs Syndr. Res. Pract.

View full text Add to dashboard Cite

“…Down syndrome patients have an extra copy of chromosome 21 and a negligible incidence of solid tumors (31). Although several genes likely contribute to this cancer protection (32), it is intriguing to note that these patients have ES levels 1.6 times higher than those of the general population (33). Further, their BP is lower than agematched controls (34,35).…”

mentioning

confidence: 95%

Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition

Sunshine¹,

Dallabrida²,

Durand³

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Antiangiogenesis therapy has become a vital part of the armamentarium against cancer. Hypertension is a dose-limiting toxicity for VEGF inhibitors. Thus, there is a pressing need to address the associated adverse events so these agents can be better used. The hypertension may be mediated by reduced NO bioavailability resulting from VEGF inhibition. We proposed that the hypertension may be prevented by coadministration with endostatin (ES), an endogenous angiogenesis inhibitor with antitumor effects shown to increase endothelial NO production in vitro. We determined that Fc-conjugated ES promoted NO production in endothelial and smooth muscle cells. ES also lowered blood pressure in normotensive mice and prevented hypertension induced by anti-VEGF antibodies. This effect was associated with higher circulating nitrate levels and was absent in eNOS-knockout mice, implicating a NO-mediated mechanism. Retrospective study of patients treated with ES in a clinical trial revealed a small but significant reduction in blood pressure, suggesting that the findings may translate to the clinic. Coadministration of ES with VEGF inhibitors may offer a unique strategy to prevent drug-related hypertension and enhance antiangiogenic tumor suppression.

show abstract

“…Significant decreases in both systolic and diastolic pressures were observed in DS patients when compared to reference populations (Morrison et al 1996;Richards & Enver, 1979). Low blood pressures have also been observed in Alzheimer's disease (AD) (Burke et al 1994;Landin et al 1993), suggesting the mechanisms driving AD contribute to the observed hypotensive tendencies of DS patients.…”

Section: Other Vascular Pathologies In Ds Patientsmentioning

confidence: 89%